Last reviewed · How we verify

NCT04808856

Treatment of Refractory Gout With ACTH or Methylprednisolone

Status unknown NA Last updated 22 March 2021
What this trial tests

NA trial testing Adrenocorticotropic Hormone in Gout in 60 participants. Status unknown.

Timeline
1 April 2021
Primary endpoint
1 April 2022
1 April 2022

Quick facts

Lead sponsorShanghai 10th People's Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date1 April 2021
Primary completion1 April 2022
Estimated completion1 April 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai 10th People's Hospital

Who can join

18 and older, any sex, with Gout. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To clarify the therapeutic effect and safety evaluation of ACTH in refractory gouty arthritis and special population, and to explore its mechanism of action.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Adrenocorticotropic Hormone

Trials testing the same drug.

Other recruiting trials for Gout

Currently open trials in the same condition.

Other Shanghai 10th People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04808856.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing